Executive summary on the treatment of type 2 diabetes mellitus in elderly or frail individuals. 2022 update of the 2018 consensus document Treatment of type 2 diabetes mellitus in the elderly

The population with type 2 DM (DM2) is highly heterogeneous, representing an important challenge for healthcare professionals. The therapeutic choice should be individualized, considering the functional status, frailty, the occurrence of comorbidities, and the preferences of patients and their caregivers. New evidence on the cardiovascular and renal protection of specific therapeutic groups and on the usefulness of new technologies for DM2 management, among other aspects, warrant an update of the consensus document on the DM2 in the elderly that was published in 2018. (C) 2022 The Authors. Published by Elsevier Espana, S.L.U.

Automated summary

The population with type 2 diabetes mellitus (DM2) is highly diverse, posing a significant challenge for healthcare professionals. Individualized treatment choices should take into account functional status, frailty, the presence of comorbidities, and the preferences of patients and their caregivers. New evidence on specific therapeutic groups' cardiovascular and renal protection, as well as the usefulness of new technologies for managing DM2, necessitates an update to the 2018 consensus document on DM2 in the elderly.